Table 3.
Fetal and neonatal subependymal giant cell astrocytoma (n = 18)
| Male/female | 14/4 = 3.5 |
| Fetusesa | 11 |
| Neonatesb | 7 |
| Gestation (weeks) | 35, range 22–40 |
| Birth weight (g) | 2653, range 2100–3600 |
| Family history of tuberous sclerosis | 1 |
| None | 9 |
| Family history not stated | 8 |
| Maternal history | |
| Maternal age | 27 years, range 17–38 |
| Gravida | G1 6, range G1–G6 |
| Delivery | |
| Vaginal | 15 |
| Cesarian section | 2 |
| Termination of pregnancy | 1 |
| Initial findings | |
| Cerebral hemisphere mass | 14 |
| Hydrocephalus | 11 |
| Concomitant cardiac rhabdomyoma | 10 |
| Seizures | 3 |
| Macrocephaly | 2 |
| Otherc | 10 |
| Location | |
| Subependyma lateral ventricle adjacent to foramen of Monro | 10 |
| Cerebral hemisphere, NOS | 4 |
| Subependyma lateral ventricle, basal ganglia, and/or thalamus | 2 |
| Within a lateral ventricle | 2 |
| Tumor characteristics | |
| Tumor greatest dimension (cm) | 4, range, 2–9 |
| Treatment | |
| Patients treated | 12d |
| Patients not treated | 5e |
| Survival with surgery alone | 9/11 (81.8)f |
| Survival SR + CT | 2/2 (100)g |
| Patients lost to follow-up | 1 |
| Outcome | |
| Fetal survival | 6/11 (54.5) |
| Neonatal survival | 5/6 (83.3)h |
| Patients treated survived | 11/12 (91.7) |
| Patients not treated survived | 1/6 (16.7) |
| Overall survivalh | 12/17 = 70.6 % |
Cases selected from the literature
CT chemotherapy, NOS not otherwise specified, SR surgical resection, XRT radiation therapy
aTumor discovered prenatally or on the first day of life
bTumor discovered within first the 2 months of life
cOther initial findings, one each: fetal hydrops, dystocia, hydramnios, lethargy, hypotonia, opisthotonus, abnormal eye movements, vomiting, hemiparesis, cyanosis, respiratory distress
dPatients treated: seven fetuses, five treated
ePatients not treated: four fetuses, five neonates
f( ) = percent
gSR + CT; one fetus and one neonate
hOne neonate was lost to follow-up